Quantum BioPharma Refutes Law Firm Claims, Defends Corporate Integrity
TL;DR
Quantum BioPharma's strong rebuttal against law firms protects investor confidence and maintains the company's competitive position in biopharmaceutical markets.
Quantum BioPharma systematically rejected vague securities claims, is reviewing the law firms' conduct, and will take appropriate action to address reputational harm.
By defending its integrity, Quantum BioPharma ensures continued focus on developing treatments for neurodegenerative disorders and improving patient healthcare outcomes.
Quantum BioPharma develops Lucid-MS to reverse myelin degradation in multiple sclerosis and holds significant royalty rights from its unbuzzd wellness product.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has issued a formal response rejecting what it described as vague and unsubstantiated claims made by The Schall Law Firm and DJS Law Group regarding alleged securities law violations. The company stated that the announcements lack factual detail or context and appear intended to mislead investors and provoke unwarranted concern. Quantum BioPharma said it is reviewing the conduct of both firms and their principals and will take appropriate action to address what it believes is a deliberate attempt to harm its reputation.
The company's response highlights the importance of factual accuracy in financial communications and the potential impact of unsubstantiated claims on investor confidence. For investors seeking comprehensive information about the company, Quantum BioPharma maintains its official newsroom at https://ibn.fm/QNTM where stakeholders can access verified corporate updates and announcements.
Quantum BioPharma operates as a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. This patented new chemical entity has been shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
The company's business model extends beyond pharmaceutical development through strategic investments and partnerships. Quantum BioPharma invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
Additionally, Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. This diversified approach to business development and revenue generation provides multiple pathways for growth and value creation for shareholders. The company's comprehensive response to the law firm announcements underscores its commitment to transparency and corporate governance while protecting shareholder interests from potentially misleading information in the market.
Curated from InvestorBrandNetwork (IBN)